Global Actinic Keratosis Treatment Market By Therapy (Surgery, Topical, and Photodynamic Therapy), By Drug Class (Nucleoside Metabolic Inhibitor, Immune Response Modifiers, NSAIDs, Photo Enhancers, and Others), By Distribution Channel, By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032
- Published date: July 2023
- Report ID: 39701
- Number of Pages: 330
- Report Overview
- Driving Factors
- Restraining Factors
- COVID-19 Impact Analysis
- By Therapy Analysis
- By Drug Class Analysis
- By Distribution Channel Analysis
- Global Actinic Keratosis Treatment Key Market Segments
- Growth Opportunity
- Latest Trends
- Regional Analysis
- Key Regions and Countries Covered in this Report
- Market Share & Key Players Analysis
- Top Key Players in Actinic Keratosis Treatment Market
- Recent Development
In 2022, the Global Actinic Keratosis Market was valued at US$ 6.4 billion. Between 2023 and 2032, this market is estimated to register a CAGR of 4.6%.
Actinic Keratosis is a disorder of epidermal keratinocytes induced by ultraviolet exposure. It is the most common precancerous that forms on skin damaged by long-term exposure to UV radiation from the sun and indoor training.
It is categorized into scaly patches, rough on skin, and most commonly found on the face, lips, back of hands, and ears photodynamic therapy, surgical procedures, topical treatments, and combination therapy. Drugs such as Diclofenac, ingenol mebutate, and 5-fluorouracil have been approved to treat actinic keratosis.
Increase in Prevalence of Actinic Keratosis
The increase in the prevalence of actinic keratosis, rising awareness about treating the disease, and rising requirement for minimally invasive therapies are anticipated to propel the market growth. The increasing consciousness concerning the dangerous effects of actinic keratosis drives the requirement for actinic therapy and increases public awareness of dermatological conditions, including actinic keratosis, driving market growth.
Actinic keratosis treatment has observed vast development in the last few years supported by several factors such as increasing incidence of skin cancer development post actinic keratosis diagnosis, and treatment options are accessible.
Rise in Government Initiatives
The global government is focusing on making healthcare facilities more affordable by implementing several advantages. These advantages have increased the number of patients participating in actinic keratosis treatment, driving market growth.
Lack of Skilled Specialists and Less Permeation of Treatment
The major factors hindering the market’s growth are the lack of skilled specialists and limited treatment permeation in developing countries. Actinic keratosis requires skilled authorities and physicians to undertake cryotherapy, chemical peels, and photodynamic therapy. But, a major lack of general doctors is anticipated to hamper the market growth.
In addition, the high cost of actinic keratosis treatments and problems, including the care modules presently accessible, is one of the main factors expected to decrease the market growth.
COVID-19 Impact Analysis
COVID-19 has a major impact on the global actinic keratosis treatment market. The treatment and diagnosis rates for COVID-19 have decreased significantly due to restrictions on visits from non-essential doctors and total lockdowns across various countries.
Various industries are owing to travel restrictions, business closures, and lockdowns. Due to the lockdown, the supply chain for medical equipment was disrupted worldwide.
By Therapy Analysis
Surgery Segment to Witness Significant Growth
The global actinic keratosis treatment market is segmented into surgery, topical, and photodynamic therapy. The surgery segment accounted for the highest market revenue share of 55.4% in 2022. This will be due to the high adoption of cryotherapy in treating actinic keratosis.
The topical segment dominated during the historical period and is estimated to hold the second-largest market share due to the growing acceptance of self-administered therapies and easy access to home-based treatment options. On the other hand, photodynamic therapy is projected to grow at 6.8% annually during the forecast period. In the future, segment growth will be driven by increased adoption of non-invasive therapies and high-efficacy photodynamic therapy over cryotherapy.
By Drug Class Analysis
The Nucleoside Metabolic Inhibitor Segment Dominates the Market Growth of the Actinic Keratosis Treatments Market
Based on drug class, the global actinic keratosis treatments market is divided into nucleoside metabolic inhibitors, immune response inhibitors, NSAIDs, photo enhancers, and others. The nucleoside metabolic inhibitor segment registered the highest market revenue share of 33% in 2022.
The highest growth is attributed to the strong commercial performance of Fluroplex and Efudex. The widespread adoption and awareness of diagnostics and treatment strategies for this condition have led to the widespread adoption of field-directed treatments such as 5-fluorouracil.
In addition, the American Academy of Dermatology has issued new guidelines that strongly recommend 5-fluorouracil as a field treatment for actinic keratosis. This will drive the segment’s growth. The photo enhancers segment is anticipated to witness the fastest growth rate during the forecast period due to the factors such as increasing awareness about actinic keratosis treatment and several strategies undertaken by market players. In addition, photodynamic therapy is on the rise and is expected to impact the market growth of photo enhancers positively.
By Distribution Channel Analysis
The Online Providers Segment Dominated the Actinic Keratosis Treatment Market
Based on the distribution channel, the global actinic keratosis treatment market is classified into online providers, drug stores & retail pharmacies, and online providers. Among these, the online provider’s segment registers the fastest CAGR during the forecast period.
Owing to the increase in preference for online purchasing of drugs over the traditional methods, rise in awareness of online pharmacy, and increase in internet users. The drug stores & retail pharmacies segment registers a CAGR of 5.1% in the actinic keratosis treatment market.
Global Actinic Keratosis Treatment Key Market Segments
- Photodynamic Therapy
By Drug Class
- Nucleoside Metabolic Inhibitor
- Immune Response Modifiers
- Photo enhancer
- Other Drug Classes
By Distribution Channel
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Providers
Novel Medications for Actinic Keratosis Treatment Will Provide Lucrative Opportunities in the Market
Researchers are developing new lotions and creams with new ingredients to penetrate the skin better and target abnormal cells more effectively. Some scientist is investigating the use of immunotherapy to treat actinic keratosis treatments. This involves using medications that stimulate the body’s immune system to attack and destroy abnormal cells. Some studies have shown that laser therapy may effectively treat actinic keratosis.
The extensive availability of generic drugs for treating actinic keratosis provides significant opportunities in the market. Additionally, increasing awareness about preventing blindness will create significant opportunities for the market.
Product Innovation is the Global Trends in the Actinic Keratosis Treatment Market
Product innovation is the major trend in obtaining popularity in the market. Significant companies are launching innovative products to sustain their position in the market. In addition, non-profit establishments are leading awareness programs to spread awareness amongst individuals regarding the procedures of actinic keratosis treatment.
North America Dominates the Global Actinic Keratosis Treatment Market During the Forecast Period
North America accounted for a significant actinic keratosis treatment market revenue share of 39.5% in 2021. It is responsible for its dominance owing to the high prevalence of diseases, growing consumer awareness, technological advancements, proactive government steps, and improvements in healthcare infrastructure. The presence of market players in North America is also one of the major factors responsible for industry growth.
Additionally, favorable government initiatives and reimbursement policies are anticipated to drive market growth. On the other hand, the Asia-Pacific market is anticipated to grow at the fastest CAGR during the forecast period. This growth can be attributed to an increase in the treatment rate for the disease, rising disposable income, and high disease prevalence in some countries, such as Australia and New Zealand.
Additionally, pharmaceutical companies are expanding their market share with various strategies.
Key Regions and Countries Covered in this Report
- North America
- The US
- Western Europe
- The UK
- Rest of Western Europe
- Eastern Europe
- The Czech Republic
- Rest of Eastern Europe
- South Korea
- Australia & New Zealand
- Rest of APAC
- Latin America
- Costa Rica
- Rest of Latin America
- Middle East & Africa
- Saudi Arabia
- South Africa
- United Arab Emirates
- Rest of MEA
Various generic pharmaceutical companies are engaged in the production and distribution of topical medications worldwide. The market is highly competitive due to the presence of various market players. Key players are adopting several strategies, such as partnerships, collaborations, and new product launches. Owing to the ongoing product releases and a focus on market penetration in developing regions, the market share of companies is anticipated to increase.
Some prominent key players in the global actinic keratosis treatments market include Novartis AG, Sun Pharmaceutical Industries Ltd., Hill Dermaceuticals, Inc., Mylan N.V., 3M Company, and others.
Top Key Players in Actinic Keratosis Treatment Market
- Sun Pharmaceutical Industries Ltd.
- Novartis AG
- Vitaris Inc.
- Hill Dermaceuticals, Inc.
- Bausch Health Companies Inc.
- Mylan N.V.
- Almirall, S.A.
- Galderma S.A.
- 3M Company
- Stanford Chemicals
- Mckesson Corporation
- Other Key Playersas
- April 2022-Almirall S.A. introduced a research collaboration with the University of Dundee to develop new methods for common and chronic dermatological diseases.
- May 2022-Actinic Keratosis Global Day become propelled by Almirall S.A. in collaboration by Euromelanoma and AEDV Fundacion Piel Sana and concurred by Skin Cancer Awareness Month.
Report Features Description Market Value (2022) US$ 6.4 Bn Forecast Revenue (2032) US$ 9.9 Bn CAGR (2023-2032) 4.6% Base Year for Estimation 2022 Historic Period 2016-2022 Forecast Period 2023-2032 Report Coverage Revenue Forecast, Market Dynamics, COVID-19 Impact, Competitive Landscape, Recent Developments Segments Covered By Therapy-Surgery, Topical, Photodynamic Therapy; By Drug Class-Nucleoside Metabolic Inhibitor, Immune Response Modifiers, NSAIDs, Photoenhancers, Other Drug Classes; By Distribution Channel-Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Providers Regional Analysis North America – The US, Canada, & Mexico; Western Europe – Germany, France, The UK, Spain, Italy, Portugal, Ireland, Austria, Switzerland, Benelux, Nordic, & Rest of Western Europe; Eastern Europe – Russia, Poland, The Czech Republic, Greece, & Rest of Eastern Europe; APAC – China, Japan, South Korea, India, Australia & New Zealand, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, & Rest of APAC; Latin America – Brazil, Colombia, Chile, Argentina, Costa Rica, & Rest of Latin America; The Middle East & Africa – Algeria, Egypt, Israel, Kuwait, Nigeria, Saudi Arabia, South Africa, Turkey, United Arab Emirates, & Rest of MEA Competitive Landscape Sun Pharmaceutical Industries Ltd., Novartis AG, Vitaris Inc., Hill Dermaceuticals, Inc., Bausch Health Companies Inc., Mylan N.V., Almirall, S.A., Galderma S.A., Other Key Players Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. Purchase Options We have three licenses to opt for Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF)
Frequently Asked Questions (FAQ)What is actinic keratosis?
Actinic keratosis is a precancerous skin condition that can develop on sun-exposed areas of the body. It is caused by the cumulative damage of ultraviolet (UV) rays from the sun or tanning beds.How big is the Actinic Keratosis Treatment Market?
The global Actinic Keratosis Treatment Market size was estimated at USD 6.4 billion in 2022 and is expected to reach USD 9.9 billion in 2032.What is the Actinic Keratosis Treatment Market growth?
The global Actinic Keratosis Treatment Market is expected to grow at a compound annual growth rate of 4.6%.Who are the key companies/players in the Actinic Keratosis Treatment Market?
Some of the key players in the Actinic Keratosis Treatment Markets are Sun Pharmaceutical Industries Ltd., Novartis AG, Vitaris Inc., Hill Dermaceuticals, Inc., Bausch Health Companies Inc., Mylan N.V., Almirall, S.A., Galderma S.A., 3M Company, Stanford Chemicals, Mckesson Corporation, Other Key PlayersasWhat are the symptoms of actinic keratosis?
Actinic keratosis typically appears as rough, scaly patches on the skin. The patches may be red, pink, or brown. They may also be crusty or have a wart-like appearance.What are the trends in the actinic keratosis treatment market?
The actinic keratosis treatment market is expected to grow in the coming years due to the increasing prevalence of actinic keratosis and the growing demand for minimally invasive procedures. There are also a number of new treatments for actinic keratosis in development, which is expected to further drive the growth of the market.
| Single User|
USD / per unit
| Multi User|
USD / per unit
| Corporate User|
USD / per unit
|Report Library Access|
|Data Set (Excel)|
|Company Profile Library Access|
|Free Custumization||No||up to 10 hrs work||up to 30 hrs work|
|Accessibility||1 User||2-5 User||Unlimited|
|Analyst Support||up to 20 hrs||up to 40 hrs||up to 50 hrs|
|Benefit||Up to 20% off on next purchase||Up to 25% off on next purchase||Up to 30% off on next purchase|
|Buy Now ($ 3,499)||Buy Now ($ 4,299)||Buy Now ($ 4,999)|